IMMX Immix Biopharma Inc

$IMMX 👀 MRD-negativity following NXC-201 may serve as an early biomarker for future hematologic and organ responses. ISA 2026

$IMMX Some guys want your shares before a binary event...which btw is not so binary as we can assume the data will be consistent with what we've seen before. Things will get worse before they get better. Seen this countless of times.

$IMMX Here we go again. Two weeks to potentially game changing data. Looking for a comparable 70%+ CR rate for patients treated 60 days. Price is down 20% since high late-August. Buy the dip!!

$IMMX Hard to be long term in biotech, but fairly certain the stock will be over 12 within 30 days. Data is solid. Ride it put team.

$IMMX If you thought the asset was undervalued yesterday, today's data should only increase that conviction. Market sees dilution. I see validation. Price will catch up. Data already has.🎯📈

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock $IMMX $XBI https://stocktwits.com/news/equity/markets/bofa-raises-immix-price-target-after-clinical-trial-result/cZMZ7RQRBWI

$IMMX One of the best parts about this company is that, once they are eventually approved, they don't need a sales force. They are already fully connected with the referral sources...

Mizuho analyst Graig Suvannavejh named Immix Biopharma his top small- and mid-cap biotech pick for September ahead of an expected clinical-data catalyst. He raised his price target to $26 from $15 while maintaining an Outperform rating, citing an updated model that includes a second potential indication for the company’s lead drug candidate, NXC-201. NXC-201 is being developed for relapsed/refractory AL amyloidosis, a rare disease involving abnormal amyloid buildup. Suvannavejh now projects peak global sales of about $1 billion in the relapsed/refractory setting and more than $2 billion in the first-line setting. He expects a Phase 2 NEXICART-2 data update by late September. Earlier interim data showed a 95% complete response rate among 20 patients as of May 2026, while the analyst is looking for a 70%-75% or higher complete response rate in the upcoming update involving more than 40 patients. $IMMX

$IMMX im up 1000% looking forward to 2000. I'm not going anywhere . Remember.. Data first - structure second - price last. This is a 100% winner and most know it. Accumulate as many shares that you can get. Focus on buying opportunity right now . Don't be fooled. people want your shares. As cheap as they can get them. We will reclaim $10 soon. The fight will be $10 to 11.50. Once that breaks the path back to 15 becomes easy.

$IMMX Think about who was short going into this. Anyone who pressed it hoping for a collapse below the offering is now sitting on a position that didn't pay, with $125M of fresh cash on the balance sheet and J.P. Morgan having just placed stock with Eventide, Janus Henderson and Ridgeback at $11. Long-only funds don't write that kind of check to flip it. On top of that, Needham and BoA takes its target to $30. The overhang is cleared, the company is funded, and the news flow from here is on our side. If you were short hoping for a single digit print, today was your chance and it didn't come. I think the shorts are trapped and I'm not selling a share. Long and staying long

$IMMX the deaths in Novartis Car-T trial and pause by BMS in their trial caused quite the sell off in Car-T stocks. It’s a buying opportunity if ncx-201 safety continues to be excellent along with super CR data.

$IMMX There a thesis that shorts started to build once AbbVie's data landed, on the view that a BCMA bispecific moving earlier shrinks the TAM for NXC-201. The case rests on an analogy to allogeneic CAR-T, which bispecifics did hurt badly. But allo's entire pitch was off-the-shelf convenience, and bispecifics delivered that better. It lost on its only differentiator. Autologous never competed there, and it has never been healthier. Carvykti did $597M in Q1 2026 alone, up 62% year on year, 36% US and 222% ex-US growth, 14,000 patients treated across 19 markets, still moving into earlier lines. J&J presented five-year CARTITUDE-2 follow-up at IMS this month. NXC-201 is autologous. One infusion, depth and durability, which is the one thing a bispecific structurally cannot offer, Hematos and Payers will appreciate.

Citizens reiterated $IMMX Market Outperform-$23 on what it believes could be best-in-class results in relapsed/refractory AL amyloidosis and continues to be buyers. $REGN $ABBV JNJ SNY AZN Citizens said in its note to investors: Yesterday, Immix reported interim results based on all 45 patients treated in the NEXICART-2 trial, showcasing what we believe could be best-in-class results in relapsed/refractory AL amyloidosis. The company concurrently raised $125MM in an underwritten offering from dedicated marquee healthcare investors. Based on the conference call and the capital raised, we remain confident in the BLA submission for NXC-201 in 1H27. With a potential commercial launch in 2028, the initiation of a front-line study slated for 2027, and a solid cash position of $357.1MM (proforma), we believe Immix represents an attractive investment opportunity and continue to be buyers amidst the current weakness in shares.

$IMMX I'd encourage folks to watch the entire Sep 29 presentation which is available on Immix's website. Gabriel has always impressed me with his command of both the business and technical issues and he did so again here. Ilya did very well this time in highlighting the most significant results, especially those which differentiate NXC-201 from other CAR-T's and from ententamig. Michael Grabow also spoke very well - represented himself well in good command of the issues, especially wrt to the opportunity for premium pricing relative to other CAR-T therapies. They seem like a very competent, aligned team now. I get that folks want the share price home run now so that they can chase the next big opportunity but this one is worth staying the course with. GLTA.

$IMMX "We have cash on hand to fund all the activities we have covered today, which includes relapse refractory NEXICART-2, BLA submission, and commercial launch, all the way through mid-2028, assuming no revenue at all. And also funding the frontline trial." This statement here from Gabe Morris (the fucking CFO for cryin' out loud) at the MS love-fest is why I got head-faked and bought calls on 38,000 shares for October. W/O the dilution, this would have SOARED! If it's still at this PPS in 10 days...I'm down ~$100,000. I got the news I expected, but the LAST thing I expected was a fund-raising dilution to go along with it. Ah, well.... All the best, Ivorthedriver P.S. Don't cry for me...I still have 20,000 shares, too. It just means I'm back in the truck this Winter instead of retired.

$IMMX Immix announces 89% CR rate in interim update across NEXICART-2 patients Immix Biopharma announced positive results of an 89% complete response, CR, rate in an interim update across all forty-five NEXICART-2 patients, advancing NXC-201 as a potential best-in-class therapy for AL Amyloidosis. All twenty-five new relapsed/refractory AL Amyloidosis patients are either in complete response or already minimum residual disease-negative. To-date, all patients achieving MRD-negativity reached CR within one year of treatment. Across all forty-five patients, NXC-201 produced an 89% CR rate as assessed by independent review committee. In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98%. No relapses to date have been observed for any patient who reached CR or MRD-negativity to-date. No neurotoxicity or enterocolitis has been observed to-date. NEXICART-2 final readout and BLA submission are planned in 2027.

$IMMX We are officially in late September 2026. Update due anyday. Tuesdays are news days. Good trial results anticipated...

$IMMX so all of yesterday and today was about stop loss hunt 🤪. We are all set for a clean launch 😍

$IMMX um anyone buy the dip?? lol two weeks squad lets see. 72% CR for new patients 60 days in….we just need similar data

$IMMX Been quite some time since I have seen price ma-nipple-action as obvious as these last couple weeks